TrialCancer chemotherapy and pharmacology2018

Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.

Steven Lacy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.